Acer Therapeutics (ACER)
(Delayed Data from OTC)
$0.66 USD
0.00 (0.00%)
Updated Nov 20, 2023 03:59 PM ET
NA Value
NA Growth NA Momentum NA VGMBalance Sheet
Fiscal Year End for Acer Therapeutics Inc falls in the month of December.
All items in Millions except Per Share data.
12/31/2023 | 12/31/2022 | 12/31/2021 | 12/31/2020 | 12/31/2019 | |
---|---|---|---|---|---|
Assets | |||||
Cash & Equivalents | -99,999 | 2 | 13 | 6 | 12 |
Receivables | NA | 0 | 5 | 0 | 0 |
Notes Receivable | NA | 0 | 0 | 0 | 0 |
Inventories | NA | 0 | 0 | 0 | 0 |
Other Current Assets | NA | 1 | 10 | 1 | 1 |
Total Current Assets | NA | 4 | 28 | 6 | 13 |
Net Property & Equipment | NA | 0 | 0 | 0 | 0 |
Investments & Advances | NA | 0 | 0 | 0 | 0 |
Other Non-Current Assets | NA | 0 | 0 | 0 | 0 |
Deferred Charges | NA | 0 | 0 | 0 | 0 |
Intangibles | NA | 8 | 8 | 8 | 8 |
Deposits & Other Assets | NA | 0 | 0 | 0 | 1 |
Total Assets | NA | 12 | 36 | 15 | 21 |
Liabilities & Shareholders Equity | 12/31/2023 | 12/31/2022 | 12/31/2021 | 12/31/2020 | 12/31/2019 |
---|---|---|---|---|---|
Notes Payable | NA | 0 | 0 | 0 | 0 |
Accounts Payable | NA | 4 | 1 | 2 | 1 |
Current Portion Long-Term Debt | NA | 0 | 0 | 0 | 0 |
Current Portion Capital Leases | NA | 0 | 0 | 0 | 0 |
Accrued Expenses | NA | 4 | 2 | 4 | 2 |
Income Taxes Payable | NA | 0 | 0 | 0 | 0 |
Other Current Liabilities | NA | 11 | 25 | 1 | 0 |
Total Current Liabilities | NA | 19 | 29 | 6 | 3 |
Mortgages | NA | 0 | 0 | 0 | 0 |
Deferred Taxes/Income | NA | 0 | 9 | 0 | 0 |
Convertible Debt | NA | 6 | 0 | 0 | 0 |
Long-Term Debt | NA | 0 | 0 | 0 | 0 |
Non-Current Capital Leases | NA | 0 | 0 | 0 | 0 |
Other Non-Current Liabilities | NA | 3 | 0 | 0 | 0 |
Minority Interest (Liabilities) | NA | 0 | 0 | 0 | 0 |
Total Liabilities | NA | 28 | 38 | 6 | 3 |
Shareholders Equity | 12/31/2023 | 12/31/2022 | 12/31/2021 | 12/31/2020 | 12/31/2019 |
---|---|---|---|---|---|
Preferred Stock | NA | 0 | 0 | 0 | 0 |
Common Stock (Par) | NA | 0 | 0 | 0 | 0 |
Capital Surplus | NA | 124 | 113 | 107 | 95 |
Retained Earnings | NA | -141 | -115 | -99 | -76 |
Other Equity | NA | 0 | 0 | 0 | 0 |
Treasury Stock | NA | 0 | 0 | 0 | 0 |
Total Shareholder's Equity | NA | -17 | -2 | 8 | 18 |
Total Liabilities & Shareholder's Equity | NA | 12 | 36 | 15 | 21 |
Total Common Equity | 0 | -17 | -2 | 8 | 18 |
Shares Outstanding | 24.40 | 15.90 | 14.30 | 12.20 | 10.10 |
Book Value Per Share | 0.00 | -1.05 | -0.12 | 0.67 | 1.82 |
Fiscal Year End for Acer Therapeutics Inc falls in the month of December.
All items in Millions except Per Share data.
6/30/2024 | 3/31/2024 | 12/31/2023 | 9/30/2023 | 6/30/2023 | |
---|---|---|---|---|---|
Assets | |||||
Cash & Equivalents | -99,999 | -99,999 | -99,999 | 1 | 2 |
Receivables | NA | NA | NA | 0 | 0 |
Notes Receivable | NA | NA | NA | 0 | 0 |
Inventories | NA | NA | NA | 5 | 5 |
Other Current Assets | NA | NA | NA | 0 | 1 |
Total Current Assets | NA | NA | NA | 6 | 7 |
Net Property & Equipment | NA | NA | NA | 0 | 0 |
Investments & Advances | NA | NA | NA | 0 | 0 |
Other Non-Current Assets | NA | NA | NA | 0 | 0 |
Deferred Charges | NA | NA | NA | 0 | 0 |
Intangibles | NA | NA | NA | 8 | 8 |
Deposits & Other Assets | NA | NA | NA | 0 | 0 |
Total Assets | NA | NA | NA | 14 | 15 |
Liabilities & Shareholders Equity | 6/30/2024 | 3/31/2024 | 12/31/2023 | 9/30/2023 | 6/30/2023 |
---|---|---|---|---|---|
Notes Payable | NA | NA | NA | 16 | 14 |
Accounts Payable | NA | NA | NA | 7 | 6 |
Current Portion Long-Term Debt | NA | NA | NA | 32 | 0 |
Current Portion Capital Leases | NA | NA | NA | 0 | 0 |
Accrued Expenses | NA | NA | NA | 7 | 5 |
Income Taxes Payable | NA | NA | NA | 0 | 0 |
Other Current Liabilities | NA | NA | NA | 1 | 19 |
Total Current Liabilities | NA | NA | NA | 62 | 43 |
Mortgages | NA | NA | NA | 0 | 0 |
Deferred Taxes/Income | NA | NA | NA | 0 | 4 |
Convertible Debt | NA | NA | NA | 0 | 0 |
Long-Term Debt | NA | NA | NA | 0 | 0 |
Non-Current Capital Leases | NA | NA | NA | 0 | 0 |
Other Non-Current Liabilities | NA | NA | 0 | 0 | |
Minority Interest (Liabilities) | NA | NA | NA | 0 | 0 |
Total Liabilities | NA | NA | NA | 62 | 48 |
Shareholders Equity | 6/30/2024 | 3/31/2024 | 12/31/2023 | 9/30/2023 | 6/30/2023 |
---|---|---|---|---|---|
Preferred Stock | NA | NA | NA | 0 | 0 |
Common Stock (Par) | NA | NA | NA | 0 | 0 |
Capital Surplus | NA | NA | NA | 132 | 132 |
Retained Earnings | NA | NA | NA | -180 | -165 |
Other Equity | NA | NA | NA | 0 | 0 |
Treasury Stock | NA | NA | NA | 0 | 0 |
Total Shareholder's Equity | NA | NA | NA | -48 | -33 |
Total Liabilities & Shareholder's Equity | NA | NA | NA | 14 | 15 |
Total Common Equity | 0 | 0 | 0 | -48 | -33 |
Shares Outstanding | 24.40 | 24.40 | 24.40 | 24.40 | 23.40 |
Book Value Per Share | 0.00 | 0.00 | 0.00 | -1.96 | -1.42 |